Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 331 -0.71%
23 May - close price
biocon.com BSE: 532523 NSE: BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Business Segments
1) Biosimilars (58% in FY25 vs 50% in FY23): [1] [2] Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. [3] It is one of the top 5 global players in biosimilars and among the top 3 in insulins. It ranks in the top 15 companies worldwide for biomanufacturing capacity and has a presence in 120+ countries, including the U.S., Europe, and emerging markets. Its product portfolio includes 10 approved biosimilars and 10 under development. [4]

The segment revenue grew by 2% YoY in FY25, driven by market share gains in the U.S. and key tender wins in the Emerging Markets. [5]

Website BSE NSE
  • Market Cap ₹ 39,710 Cr.
  • Current Price ₹ 331
  • High / Low ₹ 405 / 270
  • Stock P/E 807
  • Book Value ₹ 96.0
  • Dividend Yield 0.15 %
  • ROCE 2.12 %
  • ROE 0.44 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 27.1%
  • Company's working capital requirements have reduced from 176 days to 131 days

Cons

  • Stock is trading at 3.45 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 2.44% over past five years.
  • Company has a low return on equity of 0.45% over last 3 years.
  • Earnings include an other income of Rs.850 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 BSE MidCap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
518 442 490 555 507 513 519 563 533 511 525 563 644
491 439 462 518 551 441 452 492 480 466 488 532 582
Operating Profit 26 3 28 37 -44 72 67 71 52 45 38 31 62
OPM % 5% 1% 6% 7% -9% 14% 13% 13% 10% 9% 7% 6% 10%
61 49 1,108 60 1,918 56 64 48 39 42 74 672 63
Interest 0 0 0 21 48 48 55 56 40 55 60 65 57
Depreciation 28 29 30 29 29 30 31 31 30 30 30 34 33
Profit before tax 59 22 1,106 46 1,796 50 46 33 22 1 21 604 35
Tax % 36% 34% 11% 24% -1% 6% 25% 27% 36% 18% 85% 3% 39%
38 15 988 35 1,811 47 35 24 14 1 3 584 21
EPS in Rs 0.32 0.12 8.23 0.29 15.08 0.39 0.29 0.20 0.12 0.01 0.03 4.86 0.18
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
2,202 2,242 2,302 2,588 2,419 1,786 1,988 2,028 1,738 1,993 2,127 2,243
1,729 1,812 1,880 1,996 2,101 1,575 1,702 1,716 1,677 1,969 1,864 2,067
Operating Profit 473 430 422 592 318 210 286 312 61 24 264 176
OPM % 21% 19% 18% 23% 13% 12% 14% 15% 4% 1% 12% 8%
61 127 279 99 125 422 366 150 187 3,134 206 850
Interest 1 1 2 4 1 3 1 0 0 70 199 237
Depreciation 124 128 140 151 136 92 98 104 108 117 121 128
Profit before tax 409 428 559 536 306 537 553 359 140 2,971 150 661
Tax % 21% 16% 34% 3% 22% 8% 20% 22% 38% 4% 21% 8%
324 361 369 519 238 493 441 280 86 2,848 119 609
EPS in Rs 2.70 3.01 3.07 4.33 1.99 4.11 3.67 2.34 0.72 23.72 0.99 5.07
Dividend Payout % 31% 28% 27% 12% 25% 12% 0% 0% 70% 6% 50% 25%
Compounded Sales Growth
10 Years: 0%
5 Years: 2%
3 Years: 9%
TTM: 5%
Compounded Profit Growth
10 Years: -18%
5 Years: -31%
3 Years: -16%
TTM: -54%
Stock Price CAGR
10 Years: 16%
5 Years: -1%
3 Years: 1%
1 Year: 4%
Return on Equity
10 Years: 3%
5 Years: 1%
3 Years: 0%
Last Year: 0%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 100 100 100 100 300 300 600 600 600 600 600 600
Reserves 2,318 2,484 5,897 6,441 6,439 6,815 6,937 7,307 7,493 10,316 10,312 10,924
121 82 370 134 133 71 4 3 77 1,301 2,043 2,876
679 667 732 794 855 1,054 770 664 699 813 813 1,221
Total Liabilities 3,218 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768 15,621
949 914 894 938 903 1,101 793 798 870 961 958 1,128
CWIP 102 58 172 241 318 254 152 179 285 344 560 687
Investments 493 165 3,853 3,888 4,199 4,093 4,953 5,413 5,280 9,271 9,318 11,383
1,674 2,196 2,179 2,402 2,307 2,792 2,413 2,184 2,434 2,454 2,932 2,424
Total Assets 3,218 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768 15,621

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
186 125 208 186 355 110 387 571 48 219 -123 621
51 145 -313 104 -553 315 -189 -721 -302 -1,173 -295 -989
-187 -158 73 -238 -55 -208 -129 28 112 1,039 344 495
Net Cash Flow 50 112 -32 52 -252 217 69 -122 -142 86 -74 127

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 82 90 80 113 112 184 105 109 147 121 180 135
Inventory Days 131 148 187 190 195 371 236 197 245 208 260 296
Days Payable 99 109 146 159 202 298 230 170 172 169 175 288
Cash Conversion Cycle 115 129 121 144 105 257 111 136 220 159 265 143
Working Capital Days 65 85 78 108 87 214 154 122 181 152 244 131
ROCE % 17% 17% 10% 8% 4% 5% 5% 5% 2% 2% 3% 2%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64%
16.31% 15.79% 14.42% 10.20% 9.52% 7.97% 6.55% 5.63% 5.90% 5.93% 5.66% 5.67%
7.72% 7.76% 8.63% 11.89% 12.59% 14.08% 14.51% 13.69% 14.29% 14.44% 15.36% 15.73%
14.60% 15.17% 15.74% 16.70% 16.77% 16.92% 17.96% 19.74% 18.90% 18.74% 18.11% 17.77%
0.73% 0.63% 0.58% 0.55% 0.49% 0.39% 0.33% 0.32% 0.28% 0.25% 0.22% 0.21%
No. of Shareholders 3,41,0163,69,8163,91,3824,11,0864,12,4414,15,0464,34,3394,70,2614,43,5134,39,5034,27,7054,24,297

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls